SCHEMBL6084819

SCHEMBL6084819

Cc1ccc(C(C)C)c2oc(-c3c[nH]nc3-c3cccc(NC(=O)c4ccccc4)c3)nc12

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.44
SMN1; SMN2 Q16637 4/20 0.44
MEN1 O00255 3/20 0.44
KMT2A Q03164 3/20 0.44
KDM4E B2RXH2 1/20 0.44
POLB P06746 1/20 0.44
KCNK3 O14649 2/20 0.42
KCNK9 Q9NPC2 2/20 0.42
HPGD P15428 3/20 0.42
TSHR P16473 2/20 0.42
MAPK1 P28482 2/20 0.42
NPSR1 Q6W5P4 1/20 0.42
ALOX15 P16050 1/20 0.42
HSD17B10 Q99714 1/20 0.42
LCLAT1 Q6UWP7 1/20 0.42
GAA P10253 3/20 0.41
MAPT P10636 2/20 0.40
HTT P42858 2/20 0.39
MMP2 P08253 1/20 0.39
MMP9 P14780 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6085797 0.91 NPC1 (0.42) ALDH1A1SMN1; SMN2MEN1KMT2AKDM4E
SCHEMBL6084903 0.89 MEN1 (0.44) ALDH1A1SMN1; SMN2MEN1KMT2AKDM4E
SCHEMBL6086056 0.86 POLB (0.44) ALDH1A1SMN1; SMN2POLBKCNK3KCNK9
SCHEMBL6086423 0.86 TSHR (0.46) ALDH1A1SMN1; SMN2KMT2APOLBKCNK3
SCHEMBL6085763 0.86 TP53 (0.37) ALDH1A1SMN1; SMN2MEN1KMT2AKDM4E
SCHEMBL6085149 0.86 MAOB (0.49) ALDH1A1SMN1; SMN2KMT2APOLBMAPT
SCHEMBL6085153 0.84 MAOB (0.49)
SCHEMBL6086910 0.83 HSP90AA1 (0.39) ALDH1A1SMN1; SMN2KMT2AHPGDNPSR1
SCHEMBL6085573 0.82 BRD4 (0.42) ALDH1A1KDM4EHPGDNPSR1LMNA
SCHEMBL6085567 0.82 PTPN2 (0.42) ALDH1A1MEN1KMT2AKDM4EHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7105535-B2 Oxazolyl-pyrazole derivatives as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2006-09-12 US claimed
EP-1377589-B1 OXAZOLYL-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS PHARMACIA ITALIA SPA (IT) 2005-09-07 EP claimed
US-20040180881-A1 Oxazolyl-pyrazole derivatives as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2004-09-16 US claimed
US-7105535-B2 Oxazolyl-pyrazole derivatives as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2006-09-12 US disclosed
EP-1377589-B1 OXAZOLYL-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS PHARMACIA ITALIA SPA (IT) 2005-09-07 EP disclosed
US-20040180881-A1 Oxazolyl-pyrazole derivatives as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2004-09-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040180881-A1 Oxazolyl-pyrazole derivatives as kinase inhibitors MAP3K15, MAP3K20, MAP3K3 ALDH1A1 3486/4885SMN1; SMN2 831/4885MEN1 2891/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.